Kestra Advisory Services
PALI icon

Kestra Advisory Services’s Palisade Bio PALI Stock Holding History

Kestra Advisory Services’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$16.9K Hold
12,504
– – ﹤0.01% 3421
2026
Q2 		$26.1K Buy
+12,504
New +$24.6K ﹤0.01% 3233

Other funds holding PALI

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Propel Bio Management
Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Kestra Advisory Services's PALI Position: Q3 2026 in Review

Kestra Advisory Services held its Palisade Bio (PALI) position steady in Q3 2026 at 12,504 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3421.

Kestra Advisory Services first reported a position in PALI in Q2 2026 and has held it in 2 quarters since. The position peaked at $26.1K in Q2 2026. 71 funds tracked by Wall St. Rank hold PALI as of Q3 2026.

  • Kestra Advisory Services held 12,504 shares of Palisade Bio worth $16.9K as of Q3 2026.
  • Kestra Advisory Services left its Palisade Bio share count unchanged in Q3 2026.
  • Palisade Bio made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #3421 holding.
  • Kestra Advisory Services first reported a position in Palisade Bio in Q2 2026 and has held it in 2 quarters since.
  • Kestra Advisory Services's Palisade Bio position peaked at $26.1K in Q2 2026.
  • 71 funds tracked by Wall St. Rank held Palisade Bio as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.